Lighthouse Pharmaceuticals is a Novato, California clinical-stage biopharmaceutical company developing small-molecule therapies for chronic neurodegenerative and inflammatory diseases. Its lead program, LHP588, is an oral, once-daily gingipain inhibitor in a Phase 2 trial (SPRING) targeting P. gingivalis-positive Alzheimer's disease, supported by a $49.2M NIA grant. The company recently relocated its headquarters to the Buck Institute for Research on Aging.
1
Round
5
Tags
Apr 28, 2026
Latest raise
Funding activity · 1 round
Apr 28, 2026
$12M
Series A
Led by Double Point Ventures
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
